Transforming growth factor-β1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 721-730

  Kawada, Manabu ^a   Inoue, Hiroyukhi ^a   Arakawa, Masayuki ^a   Ikeda, Daishiro ^a  

^a Numazu Bio Medical Research Institute   (Japan)

Author keywords

IGF I; Prostate cancer; Prostate stroma; TGF ; Tumor growth

Indexed keywords

MATRILYSIN; MESSENGER RNA; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CELL CULTURE; CELL GROWTH; CELL INTERACTION; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; STROMA CELL;

CELL DIFFERENTIATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; PROSTATIC NEOPLASMS; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 42549130882     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Dvorak HF: Tumors: wounds that do not heal. N Eng J Med 315: 1650-1659, 1986.
2. Tuxhorn JA, Ayala GE and Rowley DR: Reactive stroma in prostate cancer progression. J Urol 166: 2472-2483, 2001.
3. Wernert N: The multiple roles of tumor stroma. Virchows Arch 430: 433-443, 1997.
4. Picard O, Rolland Y and Poupon MF: Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. Cancer Res 46: 3290-3294, 1986.
5. Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhau HE, Eschenbach AC and Chung LW: Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 87: 75-79, 1990.
6. Wiseman BS and Werb Z: Stromal effects on mammary gland development and breast cancer. Science 296: 1046-1049, 2002.
7. Grossfeld GD, Hayward SW, Tlsty TD and Cunha GR: The role of stroma in prostatic carcinogenesis. Endocr Relat Cancer 5: 253-270, 1998.
8. Micke P and Ostman A: Tumor-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 45: S163-S175, 2004.
9. Pollak M, Beamer W and Zhang JC: Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 77: 383-390, 1999.
10. Delinassios JG: Cytocidal effect of human fibroblasts on HeLa cells in vitro. Biol Cell 59: 69-77, 1987.
11. Jerome L, Shiry L and Leyland-Jones B: Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 10: 561-578, 2003.
12. Hwa V, Oh Y and Rosenfeld RG: The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20: 761-787, 1999.
13. Adam L, Crepin M, Lelong JC, Spanakis E and Israel L: Selective interactions between mammary epithelial cells and fibroblasts in co-culture. Int J Cancer 59: 262-268, 1994.
14. Fürstenberger G and Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol 3: 298-302, 2002.
15. Marelli MM, Moretti RM, Dondi D, Motta M and Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140: 329-334, 1999.
16. Iwamura M, Sluss PM, Casamento JB and Cockett AT: Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252, 1993.
17. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F and Toscano V: Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 23: 3825-3835, 2003.
18. Grzmil M, Hemmerlein B, Thelen P, Schweyer S and Burfeind P: Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol 202: 50-59, 2004.
19. Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G and Kaaks R: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92: 1910-1917, 2000.
20. Kawada M, Yoshimoto Y, Minamiguchi K, Kumagai H, Someno T, Masuda T, Ishizuka M and Ikeda D: A microplate assay for selective measurement of growth of epithelial tumor cells in direct coculture with stromal cells. Anticancer Res 24: 1561-1568, 2004.
21. Kawada M, Inoue H, Masuda T and Ikeda D: Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res 66: 4419-4425, 2006.
22. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD and Rowley DR: Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8: 2912-2923, 2002.
23. Peehl DM and Sellers RG: Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 232: 208-215, 1997.
24. Ronnov-Jessen L and Petersen OW: Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 68: 696-707, 1993.
25. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD and Rowley DR: Inhibition of transforming growth factor-β activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62: 6021-6025, 2002.
26. Steiner MS and Barrack ER: Transforming growth factor-β 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 6: 15-25, 1992.
27. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA and Derynck R: Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 53: 4391-4398, 1993.
28. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A and Akhurst RJ: TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86: 531-542, 1996.
29. San Francisco IF, DeWolf WC, Peehl DM and Olumi AF: Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer 112: 213-218, 2004.
30. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT and Thompson TC: Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73: 628-635, 1995.
31. Barrett-Lee P, Travers M, Luqmani Y and Coombes RC: Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer 61: 612-617, 1990.
32. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG and Moses HL: TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851, 2004.
33. Kundu SD, Kim IY, Yang T, Doglio L, Lang S, Zhang X, Buttyan R, Kim SJ, Chang J, Cai X, Wang Z and Lee C: Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)-TGF-β type II dominant negative receptor. Prostate 43: 118-124, 2000.
34. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi MH, Akimoto M and Fujita-Yamaguchi Y: Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int J Urol 3: 39-46, 1996.
35. Pekonen F, Nyman T, Ilvesmäki V and Partanen S: Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res 52: 5204-5207, 1992.
36. Rutanen E, Nyman T, Lehtovirta P, Ammälä M and Pekonen F: Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer 59: 307-312, 1994.
37. Yang D, Howard OM, Chen Q and Oppenheim JJ: Cutting edge: immature dendritic cells generated from monocytes in the presence of TGF-β1 express functional C-C chemokine receptor 6. J Immunol 163: 1734-1741, 1999.
38. Kawada M, Masuda T, Ishizuka M and Takeuchi T: 15-Deoxyspergualin inhibits Akt kinase activation and phosphatidylcholine synthesis. J Biol Chem 277: 27765-27771, 2002.
39. Miyamoto S, Yano K, Sugimoto S, Ishii G, Hasebe T, Endoh Y, Kodama K, Goya M, Chiba T and Ochiai A: Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 64: 665-671, 2004.
40. Kveiborg M, Flyvbjerg A, Eriksen EF and Kassem M: Transforming growth factor-β 1 stimulates the production of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in human bone marrow stromal osteoblast progenitors. J Endrocrinol 169: 549-561, 2001.
41. Izumi K, Kurosaka D, Iwata T, Oguchi Y, Tanaka Y, Mashima Y and Tsubota K: Involvement of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in corneal fibroblasts during corneal wound healing. Invest Ophthalmol Vis Sci 47: 591-598, 2006.
42. Simmons JG, Pucilowska JB, Keku TO and Lund PK: IGF-I and TGF-β1 have distinct effects on phenotype and proliferation of intestinal fibroblasts. Am J Physiol Gastrointest Liver Physiol 283: G809-G818, 2002.
43. Gerdes MJ, Larsen M, McBride L, Dang TD, Lu B and Rowley DR: Localization of transforming growth factor-β1 and type II receptor in developing normal human prostate and carcinoma tissues. J Histochem Cytochem 46: 379-388, 1998.
44. Peehl DM, Cohen P and Rosenfeld RG: The insulin-like growth factor system in the prostate. World J Urol 13: 306-311, 1995.
45. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC and Rosenfeld RG: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053, 1992.
46. Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB and Bowden GT: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53: 417-422, 1993.
47. Hashimoto K, Kihira Y, Matuo Y and Usui T: Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 160: 1872-1876, 1998.
48. Singh H, Dang TD, Ayala GE and Rowley DR: Transforming growth factor-β1 induced myofibroblasts regulate LNCaP cell death. J Urol 172: 2421-2425, 2004.